DEA Proposes Increased Production Quotas for Psychedelics to Support Medical Research
The Drug Enforcement Administration (DEA) has issued a draft Federal Register notice proposing a significant increase in the legal production quotas for specific psychedelic substances. This move is intended to facilitate expanded medical and scientific research into the therapeutic potential of these compounds. The proposed adjustments are slated to take effect in 2027. By increasing the allowable manufacturing limits, the agency aims to address current supply constraints that may hinder clinical studies and pharmaceutical development within the mental health sector.
Topics: drug production regulations medical research psychedelics